Affordable Access

deepdyve-link
Publisher Website

Relative incremental costs of complications of lobectomy for stage I non-small cell lung cancer.

Authors
  • Geller, Abraham D1
  • Zheng, Hui2
  • Mathisen, Douglas J3
  • Wright, Cameron D3
  • Lanuti, Michael4
  • 1 Harvard Medical School, Boston, Mass; Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Mass.
  • 2 Biostatistics Center, Massachusetts General Hospital, Boston, Mass.
  • 3 Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Mass.
  • 4 Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Mass. Electronic address: [email protected]
Type
Published Article
Journal
The Journal of thoracic and cardiovascular surgery
Publication Date
Apr 01, 2018
Volume
155
Issue
4
Pages
1804–1811
Identifiers
DOI: 10.1016/j.jtcvs.2017.11.025
PMID: 29254638
Source
Medline
Keywords
License
Unknown

Abstract

Complications, both major and minor, contribute significantly to the total 90-day direct hospital cost of lobectomy for stage I NSCLC. Analysis of 90-day postoperative outcomes more accurately captures costs. Major pulmonary complications, atrial arrhythmia, pneumonia, and prolonged air leak represent 4 high-yield targets for cost reduction. Efforts to control health care spending while improving patient outcomes might optimally focus on reducing complications that incur the greatest relative incremental cost.

Report this publication

Statistics

Seen <100 times